Additional file 5: of Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn’s disease, and clinical prognosis in inflammatory bowel disease

Figure S5. Use of medication of CD patients. (A) A table showing the use of medication on the day of blood draw (0 month) and the average end-point of monitoring period (12 months). (B) A bar graph shows the changes in HBI of the CD patients at 6–18 months after the initial blood draw and LL-37 determination. These CD patients did not use steroid medication throughout the 6–18 month monitoring period. (PDF 80 kb)